Basilea Snaps Up Another Antibiotics Program As Pipeline Swells
The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.
The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.